Vet Rec. 2003 Mar 29;152(13):381-2.
In response to increasing concern, the Committee for Veterinary Medicinal Products (CVMP) has produced this advisory notice for veterinary surgeons on the development in cats of fibrosarcomas at sites of administration of veterinary medicinal products. The advice relates principally, but not exclusively, to the subcutaneous injection of vaccines. The issue is of relevance only to cats and no extrapolation should be made to other species or to man. At the current state of knowledge, it is not possible to provide specific advice on the risk that any product, or any type of product, might represent in terms of inducing a fibrosarcoma at the site of administration. However, following the precautionary principle, the CVMP considers that information on this issue should be made available to veterinary surgeons in order that they can have an informed discussion with owners of the benefits and risks of therapeutic interventions in cats, particularly in relation to vaccination and re-vaccination. The CVMP wishes to emphasise that modern vaccines continue to represent the only safe and effective means of protecting cats against serious infectious diseases and this should be taken fully into account in any discussion between veterinary surgeons and owners of cats.
针对日益增长的关注，兽药产品委员会（CVMP）为兽医发布了这份咨询通知，内容涉及兽药产品给药部位猫纤维肉瘤的发展情况。该建议主要但不限于皮下注射疫苗。此问题仅与猫有关，不应外推至其他物种或人类。就目前的知识水平而言，无法就任何产品或任何类型的产品在给药部位诱发纤维肉瘤方面可能存在的风险提供具体建议。然而，遵循预防原则，CVMP认为应向兽医提供有关此问题的信息，以便他们能够与猫主人就是否进行治疗干预（特别是疫苗接种和再次接种）的益处和风险进行充分知情的讨论。CVMP希望强调，现代疫苗仍然是保护猫免受严重传染病侵害的唯一安全有效手段，兽医与猫主人的任何讨论都应充分考虑这一点。
